相关临床试验
64
12 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
5
7.8%
已完成
39
60.9%
尚未招募
7
10.9%
招募中
13
20.3%
暂无批准数据
- Healthcare organizations have invested heavily in digital outreach tools, yet patients still miss appointments, skip intake, and disengage from care plans because generic messaging fails to drive action. - Nearly 72% of patients schedule appointments by phone, and an 18% national no-show rate costs organizations roughly $150 billion annually, signaling fragmented patient engagement. - Experts argue the solution is AI orchestration—coordinating communication around the patient journey to reduce unnecessary inbound calls and proactively remove barriers to care. - A patient-first, agentic AI approach that personalizes channel, language, and timing can improve adherence, reduce staff burden, and yield more predictable revenue.
- Philips received FDA 510(k) clearance for a new reusable SpO₂ clip sensor with optical refinements that improve signal quality and measurement consistency across diverse patient populations. - The device demonstrated an accuracy root mean square value of 1.6% in desaturation studies, nearly twice as accurate as the 3% ISO standard recognized by the FDA. - Accuracy varied by less than 0.5% between people with light and dark skin pigmentation, addressing longstanding concerns about pulse oximeter disparities in darker-skinned patients. - The clearance comes amid heightened regulatory scrutiny, with the FDA's 2025 draft guidance on pulse oximeter testing still awaiting finalization.
- The SEISMIC consortium has secured €23.5 million in public funding from the Innovative Health Initiative to develop minimally invasive neurosurgical techniques for treating brain hemorrhages and tumors. - Hospital Clínic-IDIBAPS will lead clinical research projects focused on cerebral hemorrhagic stroke treatment, coordinated by neurosurgeon Ramon Torné with €1.4 million in dedicated funding. - The five-year program will develop integrated technologies including real-time surgical navigation combining ultrasound and X-ray imaging, targeting three critical neurological conditions where surgery is essential for patient survival. - Current neurosurgical procedures rely on large skull openings and fragmented imaging systems that disrupt workflows, while SEISMIC aims to transform these high-risk procedures into safer, faster interventions.
- Ibex Medical Analytics announced a significant expansion of its biopharma business, extending its AI-powered pathology platform from late-stage biomarker development into earlier translational research and trial optimization. - The company's platform, already deployed across more than 50 health systems worldwide, now supports exploratory, preclinical, and clinical evidence generation while providing foundation for companion diagnostic programs. - New AI modules will focus on HER2 quantification, tumor microenvironment analysis of rare cancer subtypes, and biomarkers for antibody-drug conjugates and immune-oncology strategies. - The expanded platform aims to accelerate drug development pipelines and improve precision in oncology by integrating multiple dimensions of cancer biology in a rapid and objective manner.
- The iMODERN trial, the largest global study to date using iFR technology in heart attack patients, found no significant difference in major outcomes between immediate and delayed treatment of additional narrowed arteries over three years. - The study enrolled 1,146 patients across 41 hospitals in 14 countries and was published in The New England Journal of Medicine, confirming both treatment approaches are equally safe and effective. - Complementary ILIAS ANOCA study results demonstrated that physiology-guided coronary function testing significantly improved angina symptoms and quality of life in patients with no obstructive coronary arteries. - These findings provide cardiologists with evidence-based flexibility to tailor treatment timing decisions for individual heart attack patients without compromising long-term outcomes.
- GE HealthCare has acquired brain analysis company Icometrix for an undisclosed sum to expand its Alzheimer's disease diagnostic capabilities. - The acquisition centers on Icometrix's FDA-cleared icobrain aria software, which detects and quantifies ARIA side effects from new Alzheimer's drugs like Leqembi and Kisunla. - Clinical validation showed the AI-powered software significantly improved radiologists' detection and diagnosis of brain swelling and bleeding complications across 199 test cases. - The deal represents GE HealthCare's continued expansion in Alzheimer's diagnostics, following its previous acquisition of MIM Software and integration of amyloid assessment tools.
- The FDA has granted 510(k) clearance to an updated version of the Philips UroNav System, featuring advanced annotation workflow for enhanced precision in minimally invasive prostate cancer focal therapy procedures. - The platform integrates pre-procedural MRI imaging with real-time intra-procedural ultrasound to provide clinicians with comprehensive visualization of target areas during treatment. - The system works in tandem with DynaCAD Urology to support focal therapy planning, delivery, and review, allowing urologists to edit prostate segmentation and add targets as needed. - Clinical experts highlight the platform's potential to personalize therapy with greater accuracy while sparing patients unnecessary side effects of traditional treatments.
- Philips has received FDA 510(k) clearance for SmartSpeed Precise, an AI-powered MRI reconstruction tool that can scan up to three times faster while producing images up to 80% sharper than earlier methods. - The software integrates Philips' Compressed SENSE acceleration engine with dual AI models for denoising and image sharpening, offering a single-click workflow to address staff shortages and patient backlogs. - Clinical testing at University Hospital Bonn demonstrated breast MRI acquisition times reduced by up to 50% with improved image quality compared to previous protocols. - The technology is now available for all Philips 1.5-tesla and 3-tesla MRI systems, including existing installed base systems as an upgrade option.
- Philips and Polarean have advanced their strategic partnership to bring radiation-free Xenon MRI technology to children with obstructive lung diseases, potentially extending access to patients as young as six years old pending FDA approval. - The collaboration integrates Polarean's XENOVIEW 3T Chest Coil with Philips' 3.0T MRI systems, enabling clinicians to visualize lung ventilation in real-time with just two 10-second breath-holds, completing scans in under one minute. - This technology addresses a critical unmet need in pediatric respiratory care, offering a safer alternative for monitoring chronic conditions like asthma and cystic fibrosis without radiation exposure, particularly important for children requiring repeated imaging.
- The DEFINE GPS trial has completed enrollment, evaluating iFR co-registration technology to improve precision in percutaneous coronary interventions (PCI) and reduce residual ischemia. - Previous research found 25% of patients leave catheterization labs with residual ischemia after PCI, with 80% of these cases potentially resolvable through additional intervention guided by physiologic assessment. - The trial's primary endpoint measures major adverse cardiac events over two years, with results potentially influencing international guidelines and establishing a new standard for successful PCI procedures.
